Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cue Biopharma ( (CUE) ) just unveiled an announcement.
On June 30, 2025, Cue Biopharma, Inc. and MIL 40G, LLC amended their License Agreement, resulting in a reduced monthly rental rate from $235,883.98 to $147,545.69, effective immediately, with a 4% increase scheduled for April 15, 2027. Additionally, the agreement’s term was extended to April 14, 2028, and Cue Biopharma received a partial rent credit for June 2025, potentially improving its financial standing and operational flexibility.
The most recent analyst rating on (CUE) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Cue Biopharma stock, see the CUE Stock Forecast page.
Spark’s Take on CUE Stock
According to Spark, TipRanks’ AI Analyst, CUE is a Neutral.
Cue Biopharma’s stock score is primarily driven down by its financial struggles, highlighted by negative profitability and cash flow issues. Technical analysis shows some market activity but remains bearish overall. Valuation is notably weak due to negative earnings, making the stock less attractive.
To see Spark’s full report on CUE stock, click here.
More about Cue Biopharma
Cue Biopharma, Inc. operates in the biopharmaceutical industry, focusing on developing innovative biologics to modulate the immune system for treating cancers and autoimmune diseases.
Average Trading Volume: 215,565
Technical Sentiment Signal: Sell
Current Market Cap: $55.83M
See more data about CUE stock on TipRanks’ Stock Analysis page.